|
Name |
2(3H)-Phenanthrenone, 4,4a,9,10-tetrahydro-4a-methyl-
|
Molecular Formula | C15H16O | |
IUPAC Name* |
4a-methyl-3,4,9,10-tetrahydrophenanthren-2-one
|
|
SMILES |
CC12CCC(=O)C=C1CCC3=CC=CC=C23
|
|
InChI |
InChI=1S/C15H16O/c1-15-9-8-13(16)10-12(15)7-6-11-4-2-3-5-14(11)15/h2-5,10H,6-9H2,1H3
|
|
InChIKey |
FSPGJSRKHCJARC-UHFFFAOYSA-N
|
|
Synonyms |
2(3H)-Phenanthrenone, 4,4a,9,10-tetrahydro-4a-methyl-; 6606-34-4; 2(3H)-Phenanthrone, 4,4a,9,10-tetrahydro-4a-methyl-; 4a-Methyl-4,4a,9,10-tetrahydro-2(3H)-phenanthrenone; ghl.PD_Mitscher_leg0.1301; 4a-methyl-4,4a,9,10-tetrahydro-2(3H)-phenanthrone; SCHEMBL7789528; DTXSID30345855; 4a-methyl-3,4,9,10-tetrahydro-phenanthren-2-one; 4,4a,9,10-Tetrahydro-4a-methyl-2(3H)-phenanthrenone; (+/-)-4a-methyl-4,4a,9,10-tetrahydro-2(3H)-phenanthrenone
|
|
CAS | 6606-34-4 | |
PubChem CID | 607587 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 212.29 | ALogp: | 2.7 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 17.1 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.636 |
Caco-2 Permeability: | -4.793 | MDCK Permeability: | 0.00001940 |
Pgp-inhibitor: | 0.996 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.006 |
Blood-Brain-Barrier Penetration (BBB): | 0.099 | Plasma Protein Binding (PPB): | 95.52% |
Volume Distribution (VD): | 0.584 | Fu: | 2.97% |
CYP1A2-inhibitor: | 0.342 | CYP1A2-substrate: | 0.815 |
CYP2C19-inhibitor: | 0.884 | CYP2C19-substrate: | 0.939 |
CYP2C9-inhibitor: | 0.284 | CYP2C9-substrate: | 0.939 |
CYP2D6-inhibitor: | 0.046 | CYP2D6-substrate: | 0.78 |
CYP3A4-inhibitor: | 0.177 | CYP3A4-substrate: | 0.831 |
Clearance (CL): | 5.119 | Half-life (T1/2): | 0.719 |
hERG Blockers: | 0.052 | Human Hepatotoxicity (H-HT): | 0.341 |
Drug-inuced Liver Injury (DILI): | 0.041 | AMES Toxicity: | 0.054 |
Rat Oral Acute Toxicity: | 0.065 | Maximum Recommended Daily Dose: | 0.488 |
Skin Sensitization: | 0.196 | Carcinogencity: | 0.654 |
Eye Corrosion: | 0.004 | Eye Irritation: | 0.12 |
Respiratory Toxicity: | 0.207 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000038 | 0.393 | D0UM7O | 0.379 | ||||
ENC000345 | 0.352 | D0Z9NZ | 0.319 | ||||
ENC000681 | 0.316 | D08EOD | 0.318 | ||||
ENC002076 | 0.306 | D06XZR | 0.317 | ||||
ENC000518 | 0.300 | D0YG7M | 0.310 | ||||
ENC002250 | 0.295 | D0N7AD | 0.306 | ||||
ENC004993 | 0.292 | D03GET | 0.302 | ||||
ENC006142 | 0.290 | D0O7JW | 0.299 | ||||
ENC001319 | 0.290 | D0E6YQ | 0.286 | ||||
ENC005244 | 0.290 | D05IHU | 0.282 |